Valion Bio names Dean Zikria interim CEO, shifts board leadership
The company also elevated Thomas Jensen to board chair and named Jared Malbin audit committee chair as Sheryle Bolton departed the board.
SEC filing
Latest
5 stories
Wednesday, September 23
Tuesday, September 1
Valion Bio names Lisa Wolf president and COO, adds two directors
The Nasdaq-listed biotech also disclosed a $7.74 million financing with 3i, LP tied to overdue payments under its Series C preferred stock terms.
SEC filing (2)
Monday, August 17
Valion Bio expects $1.5 million preferred stock closing with 3i, LP on Aug. 17
The company also removed CEO Michael Handley, elevated CFO Lisa Wolf to add the COO title, and disclosed preliminary special meeting vote results.
SEC filing
Thursday, August 6
Valion Bio clears first Entolimod milestone, settles $750,000 payment in preferred stock
The company issued nearly 1,288 preferred shares to Statera and Avenue Venture Opportunities Fund to cover a milestone payment tied to its Toll-like Receptor 5 agonist program.
SEC filing
Friday, July 17
Valion Bio files S-1 for offering of up to 29.4 million shares and warrants
The San Antonio biopharmaceutical company registered a Nasdaq offering priced around $0.51 per share, with proceeds slated for its Entolimod program and general corporate use.
SEC filing